文献速递心律失常心力衰竭与心肌病

靶向治疗基础疾病改善持续性房颤窦性心律维持:RACE 3试验结果

Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
PubMed 文献 · Eur Heart J · 2018-01-01

RACE 3试验将245例早期持续性房颤伴轻中度心衰患者随机分为靶向治疗基础疾病组和常规治疗组,两组均接受房颤和心衰的病因治疗及节律控制治疗。干预组额外启动盐皮质激素受体拮抗剂、他汀、ACEI/ARB及心脏康复。1年时干预组窦性心律维持率75% vs 常规组63%(OR 1.765,95%CI下限1.021,P=0.042),表明靶向治疗基础疾病可改善窦性心律维持。

要点

  • 持续性房颤伴轻中度心衰患者,靶向治疗基础疾病可提高1年窦性心律维持率。
  • 干预措施包括MRA、他汀、ACEI/ARB及心脏康复,其中MRA和他汀使用率显著提高。
  • 1年窦性心律:干预组75% vs 常规组63%,OR 1.765(95%CI下限1.021,P=0.042)。

核心结论

  • 靶向治疗基础疾病可改善持续性房颤患者的窦性心律维持。

研究设计与样本

  • 随机对照试验,纳入245例早期持续性房颤伴轻中度心衰患者,干预组119例,常规组126例。

主要发现

  • 1年时窦性心律在干预组为89例(75%),常规组为79例(63%)。
  • 干预组MRA使用101例(85%)vs 常规组5例(4%),P<0.001。
  • 干预组他汀使用111例(93%)vs 常规组61例(48%),P<0.001。
  • 心脏康复在109例(92%)患者中完成。
  • ACEI/ARB使用两组无差异。

关键数值与推荐

  • 主要终点为1年时7天Holter监测下的窦性心律,OR 1.765,95%CI下限1.021,P=0.042。

临床怎么用

  • 对早期持续性房颤伴轻中度心衰患者,除节律控制外应积极靶向治疗基础疾病,包括MRA、他汀、ACEI/ARB及心脏康复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Atrial fibrillation (AF) is a progressive disease. Targeted therapy of underlying conditions refers to interventions aiming to modify risk factors in order to prevent AF. We hypothesised that targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent AF. METHODS AND RESULTS: We randomized patients with early persistent AF and mild-to-moderate heart failure (HF) to targeted therapy of underlying conditions or conventional therapy. Both groups received causal treatment of AF and HF, and rhythm control therapy. In the intervention group, on top of that, four therapies were started: (i) mineralocorticoid receptor antagonists (MRAs), (ii) statins, (iii) angiotensin converting enzyme inhibitors and/or receptor blockers, and (iv) cardiac rehabilitation including physical activity, dietary restrictions, and counselling. The primary endpoint was sinus rhythm at 1 year during 7 days of Holter monitoring. Of 245 patients, 119 were randomized to targeted and 126 to conventional therapy. The intervention led to a contrast in MRA (101 [85%] vs. 5 [4%] patients, P < 0.001) and statin use (111 [93%] vs. 61 [48%], P < 0.001). Angiotensin converting enzyme inhibitors/angiotensin receptor blockers were not different. Cardiac rehabilitation was completed in 109 (92%) patients. Underlying conditions were more successfully treated in the intervention group. At 1 year, sinus rhythm was present in 89 (75%) patients in the intervention vs. 79 (63%) in the conventional group (odds ratio 1.765, lower limit of 95% confidence interval 1.021, P = 0.042). CONCLUSIONS: RACE 3 confirms that targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent AF. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov NCT00877643.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018. PMID: 29401239. doi:10.1093/eurheartj/ehx739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。